105 related articles for article (PubMed ID: 25427011)
1. [Clinical features of 314 patients with relapsing-remitting multiple sclerosis].
Nogales-Gaete J; Aracena R; Cepeda-Zumaeta S; Eloiza C; Agurto P; Díaz V; Labbé S; Martínez S; Flores J; Araya C
Rev Med Chil; 2014 May; 142(5):559-66. PubMed ID: 25427011
[TBL] [Abstract][Full Text] [Related]
2. [Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs].
Nogales-Gaete J; Aracena R; Díaz V; Zitko P; Eloiza C; Cepeda-Zumaeta S; Agurto P; González C
Rev Med Chil; 2012 Nov; 140(11):1437-44. PubMed ID: 23677190
[TBL] [Abstract][Full Text] [Related]
3. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
4. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
Sayao AL; Bueno AM; Devonshire V; Tremlett H;
Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
[TBL] [Abstract][Full Text] [Related]
5. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
[TBL] [Abstract][Full Text] [Related]
6. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
7. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis.
Sundgren M; Maurex L; Wahlin Å; Piehl F; Brismar T
Arch Clin Neuropsychol; 2013 Mar; 28(2):144-55. PubMed ID: 23291310
[TBL] [Abstract][Full Text] [Related]
8. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
[TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
[TBL] [Abstract][Full Text] [Related]
10. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
11. [Multiple sclerosis and depression].
Sánchez López MP; Olivares Pérez T; Nieto Barco A; Hernández Pérez MA; Barroso Ribal J
Rev Neurol; 2004 Mar 16-31; 38(6):524-9. PubMed ID: 15054715
[TBL] [Abstract][Full Text] [Related]
12. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
[TBL] [Abstract][Full Text] [Related]
13. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis.
Portaccio E; Goretti B; Zipoli V; Nacmias B; Stromillo ML; Bartolozzi ML; Siracusa G; Guidi L; Federico A; Sorbi S; De Stefano N; Amato MP
Mult Scler; 2009 Dec; 15(12):1489-94. PubMed ID: 19965518
[TBL] [Abstract][Full Text] [Related]
14. Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients.
Tsivgoulis G; Triantafyllou N; Papageorgiou C; Evangelopoulos ME; Kararizou E; Sfagos C; Vassilopoulos D
Acta Neurol Scand; 2007 Jan; 115(1):67-72. PubMed ID: 17156268
[TBL] [Abstract][Full Text] [Related]
15. [Neuropsychology of mildly disabled patients with relapsing-remitting multiple sclerosis].
Santiago Rolanía O; Guàrdia Olmos J; Arbizu Urdiain T
Psicothema; 2006 Feb; 18(1):84-7. PubMed ID: 17296014
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
17. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
Amato MP; Portaccio E; Goretti B; Zipoli V; Battaglini M; Bartolozzi ML; Stromillo ML; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
Arch Neurol; 2007 Aug; 64(8):1157-61. PubMed ID: 17698706
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up.
Amato MP; Goretti B; Ghezzi A; Hakiki B; Niccolai C; Lori S; Moiola L; Falautano M; Viterbo RG; Patti F; Cilia S; Pozzilli C; Bianchi V; Roscio M; Martinelli V; Comi G; Portaccio E; Trojano M;
Neurology; 2014 Oct; 83(16):1432-8. PubMed ID: 25217060
[TBL] [Abstract][Full Text] [Related]
19. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
[TBL] [Abstract][Full Text] [Related]
20. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
